Regeneron and Sanofi announced that the EC has expanded the marketing authorisation for Dupixent® (dupilumab) in the...
Zhejiang Doer Biologics and Merck clinical trials
Zhejiang Doer Biologics announced a clinical trial collaboration agreement with Merck to evaluate DR30303 (humanized...
Merck and Moderna announce success in mRNA-4157/V940/Keytruda® trial
Merck and Moderna announced that the Phase 2b KEYNOTE-942/mRNA-4157-P201 trial of mRNA-4157/V940 (investigational...
FDA approves Fresenius’ citrate-free biosimilar adalimumab Idacio®
Fresenius Kabi announced that the FDA has approved its citrate-free biosimilar adalimumab (Idacio®) for all Humira®...
Amgen to acquire Horizon Therapeutics
Amgen announced that it will acquire Horizon Therapeutics for $27.8 billion. Amgen reported that it expects the...
EMA reviewing Stelara® (ustekinumab) biosimilar application
The EMA reported that it is reviewing an application for biosimilar ustekinumab. If approved, this will be the first...
Paras Biopharma creates new division for biosimilars “Paras Biologics”
Finland’s Paras Biopharmaceuticals announced the split of its biologics and biosimilars business units, with the...
New study reports glofitamab is effective in diffuse large B-cell lymphoma
A new Roche study published in the New England Journal of Medicine reported that first in class bispecific...
FDA accepts Biogen aBLA for biosimilar tocilizumab (Genentech’s Actemra®)
Biogen announced that the FDA accepted its aBLA for BIIB800 (biosimilar tocilizumab) referencing Genentech’s...
Alvotech shares start trading on Nasdaq Iceland Main Market
Alvotech announced that its shares started trading on the Nasdaq Iceland Main Market in addition to the NASDAQ and...
Alvotech and STADA launch Hukyndra® (biosimilar adalimumab) in additional European countries
Alvotech and STADA announced the launch of their high-concentration, citrate free biosimilar adalimumab Hukyndra® in...
Regeneron seeks expedited motion in aflibercept dispute
In its aflibercept suit against Mylan in the Northern District of West Virginia Regeneron filed an expedited motion...
Merck’s development of subcutaneous formulations of Keytruda® (pembrolizumab)
Reuters reported that Merck hopes to patent subcutaneous formulations of Keytruda® (pembrolizumab). Merck has several...
Alvotech announces changes to share listings and leadership team
Alvotech announced that Nasdaq Iceland has approved its request for the admission of its shares on the Nasdaq Iceland...
Erasca and Pierre Fabre sign agreement for encorafenib and cetuximab
Erasca announced it has signed a clinical trial collaboration and supply agreement with Pierre Fabre for BRAFTOVI...
Janssen sues Amgen over Stelara® (ustekinumab) biosimilar
Janssen sued Amgen in the District Court of Delaware in relation to Amgen’s ABP654 (biosimilar ustekinumab). Janssen...